 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CD123 CAR-T cell therapy / Chongqing Precision Biotech
Trial completion date, Trial primary completion date: Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=40, Recruiting, Sponsor: Chongqing Precision Biotech Co., Ltd
Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- | CD123 CAR-T cell therapy / Chongqing Precision Biotech
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 18, 2023
P1/2, N=45, Recruiting, Sponsor: Chongqing Precision Biotech Co., Ltd
Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Dec 2021 --> Dec 2023
- | CD123 CAR-T cell therapy / Chongqing Precision Biotech
New P1/2 trial: Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 16, 2020
P1/2, N=40, Recruiting, Sponsor: Chongqing Precision Biotech Co., Ltd
- | CD123 CAR-T cell therapy / Chongqing Precision Biotech
New P1/2 trial, CAR T-Cell Therapy: CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Feb 11, 2020
P1/2, N=45, Recruiting, Sponsor: Chongqing Precision Biotech Co., Ltd